Overview

A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the study is to investigate the role of SB 8.4% as adjuvant therapy in the treatment of COVID- 19 patients proved to be RT-PCR positive (mild, moderate and severe).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University
Criteria
Inclusion Criteria:

- all consecutive patients suspected as COVID-19 presented to the respiratory evaluation
zone and outpatient clinic of our university will be subjected to RT-PCR test for
COVID.

- Patients proved to be RT-PCR positive will be included in the present study.

Exclusion Criteria:

- pregnant ladies

- who will refuse enrollment or discontinue follow up.